Evidence map›Paper›PMID 42299626›Full record

Observational studyEuropean heart journal. Cardiovascular pharmacotherapy2026

Bleeding risk assessment in patients with new-onset atrial fibrillation after coronary surgery: a proof-of-concept study.

Mary Rezk, Amar Taha, Andreas Martinsson, Susanne J Nielsen, Tomas Gudbjartsson, Lennart Bergfeldt, Florian E M Herrmann, Emma C Hansson, Anders Jeppsson

Abstract readObservational Study
In one paragraph

Observational study in European heart journal. Cardiovascular pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Emerging therapies and evolving paradigms in cardiovascular pharmacotherapy.European heart journal. Cardiovascular pharmacotherapy · 2026
    Article
  5. The anticoagulation dilemma in post-operative atrial fibrillation after cardiac surgery.European heart journal. Cardiovascular pharmacotherapy · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Mary RezkDepartment of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg 413 45, Sweden.
Amar TahaDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 90, Sweden.ORCID 0000-0002-9372-4387
Andreas MartinssonDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 90, Sweden.ORCID 0000-0003-1461-0777
Susanne J NielsenDepartment of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg 413 45, Sweden.ORCID 0000-0001-6811-1418
Tomas GudbjartssonDepartment of Cardiothoracic Surgery, Landspitali University Hospital, Reykjavik 101, Iceland.ORCID 0000-0002-7281-5749
Lennart BergfeldtDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 90, Sweden.
Florian E M HerrmannDepartment of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg 413 90, Sweden.
Emma C HanssonDepartment of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg 413 45, Sweden.
Anders JeppssonDepartment of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg 413 45, Sweden.ORCID 0000-0003-2356-2295

Funding

Swedish Heart-Lung Foundation 20210433Swedish Heart-Lung Foundation ALFGBG-942665Swedish Heart-Lung Foundation ALFGBG-966204Swedish Heart-Lung Foundation ALFGBG-977905Västra Götaland Region VGFOUREG-969376
6 · The paper itself

Abstract

aimsCurrent guidelines recommend considering long-term oral anticoagulation in patients with new-onset post-operative atrial fibrillation (POAF) after cardiac surgery, balancing stroke and bleeding risk. However, no specific approach to bleeding risk assessment is provided. We explored in a proof-of-concept study whether a bleeding risk score can identify patients with POAF after coronary artery bypass grafting (CABG) with increased risk of post-discharge major bleeding. METHODS AND

resultsThis observational cohort study included 4436 patients with POAF after CABG in 2009-2020 without oral anticoagulation. The four-item PRECISE-DAPT score (based on age, creatinine clearance, preoperative haemoglobin concentration, and previous bleeding) was calculated for all patients. Bleeding risk was defined as high (≥25 points), medium (16-24 points), or low (≤15 points). Associations between bleeding risk and major bleeding events during the first post-operative year were assessed by Cox regression. Discrimination was evaluated with C-statistics, and calibration was assessed by comparing expected and observed bleeding rates. Major bleeding occurred in 2.1% of patients during the first year. The score classified 36.0% of patients as high bleeding risk. The hazard ratio for high vs. low bleeding risk was 4.81 (95% CI 2.59-8.96). The area under the receiver operating characteristic curve was 0.68 (95% CI 0.63-0.73). Calibration showed good agreement between expected and observed bleeding events in patients with an annual bleeding risk up to 7%.

conclusionA bleeding risk score can be used to stratify patients with POAF after CABG into groups with different post-discharge bleeding risk. Further studies are necessary to identify the optimal risk score and its role in oral anticoagulation decision pathway to improve clinical outcomes.

Indexed as

AnticoagulantsAtrial FibrillationCoronary Artery BypassDecision Support TechniquesPostoperative HemorrhageAdministration, OralAgedFemaleHumansMaleMiddle AgedPredictive Value of TestsProof of Concept StudyRisk AssessmentRisk FactorsTime FactorsAnticoagulantsAnticoagulationBleeding riskPost-operative atrial fibrillation

Identifiers

PMID42299626
PMCPMC13588634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.